Vor Biopharma (NASDAQ:VOR) Director Sells $2,730,322.41 in Stock

Key Points

• Vor Biopharma Director Ra Capital Management, L.P. sold 92,023 shares for approximately $2.73 million on October 20th, contributing to a series of significant stock transactions by the firm in mid-October.
• The company's recent earnings report showed a loss of ($43.60) per share, significantly missing the analysts' consensus estimate of ($11.40).
• Analysts' ratings for Vor Biopharma are mixed, with one firm rating it a Strong Buy and others issuing ratings from Strong Sell to Buy; the average price target is notably high at $77.83.

Vor Biopharma Inc. (NASDAQ:VOR - Get Free Report) Director Ra Capital Management, L.P. sold 92,023 shares of the business's stock in a transaction that occurred on Monday, October 20th. The stock was sold at an average price of $29.67, for a total value of $2,730,322.41. The sale was disclosed in a document filed with the SEC, which is accessible through this link.

Ra Capital Management, L.P. also recently made the following trade(s):

• On Tuesday, October 21st, Ra Capital Management, L.P. sold 25,027 shares of Vor Biopharma stock. The shares were sold at an average price of $28.11, for a total value of $703,508.97.
• On Friday, October 17th, Ra Capital Management, L.P. sold 260,859 shares of Vor Biopharma stock. The shares were sold at an average price of $29.39, for a total value of $7,666,646.01.
• On Thursday, October 16th, Ra Capital Management, L.P. sold 151,803 shares of Vor Biopharma stock. The shares were sold at an average price of $29.45, for a total value of $4,470,598.35.
• On Wednesday, October 15th, Ra Capital Management, L.P. sold 51,363 shares of Vor Biopharma stock. The shares were sold at an average price of $30.55, for a total value of $1,569,139.65.

Vor Biopharma Price Performance

Shares of VOR traded down $1.27 during mid-day trading on Wednesday, hitting $26.50. 294,423 shares of the company's stock were exchanged, compared to its average volume of 524,332. Vor Biopharma Inc. has a fifty-two week low of $2.62 and a fifty-two week high of $65.80. The stock has a market cap of $181.53 million, a price-to-earnings ratio of -0.10 and a beta of 2.07. The company has a 50 day simple moving average of $35.96.

Vor Biopharma (NASDAQ:VOR - Get Free Report) last issued its quarterly earnings data on Tuesday, August 12th. The company reported ($43.60) earnings per share for the quarter, missing analysts' consensus estimates of ($11.40) by ($32.20).

Institutional Trading of Vor Biopharma

Several hedge funds have recently modified their holdings of VOR. OMERS ADMINISTRATION Corp acquired a new stake in Vor Biopharma in the 1st quarter valued at $100,000. Goldman Sachs Group Inc. raised its stake in shares of Vor Biopharma by 218.2% during the 1st quarter. Goldman Sachs Group Inc. now owns 84,945 shares of the company's stock worth $61,000 after purchasing an additional 58,247 shares during the period. Money Concepts Capital Corp raised its stake in shares of Vor Biopharma by 106.1% during the 1st quarter. Money Concepts Capital Corp now owns 51,535 shares of the company's stock worth $37,000 after purchasing an additional 26,535 shares during the period. Jane Street Group LLC bought a new stake in Vor Biopharma in the 1st quarter valued at about $140,000. Finally, XTX Topco Ltd bought a new stake in Vor Biopharma in the 2nd quarter valued at about $66,000. Institutional investors own 97.29% of the company's stock.

Wall Street Analyst Weigh In

VOR has been the subject of a number of research analyst reports. Zacks Research downgraded shares of Vor Biopharma from a "hold" rating to a "strong sell" rating in a research report on Monday, October 13th. HC Wainwright reiterated a "buy" rating and set a $60.00 target price on shares of Vor Biopharma in a research report on Thursday, August 14th. Stifel Nicolaus upgraded shares of Vor Biopharma from a "hold" rating to a "buy" rating and set a $55.00 price target on the stock in a research report on Wednesday, September 24th. Wall Street Zen lowered shares of Vor Biopharma to a "strong sell" rating in a research report on Saturday, June 28th. Finally, Baird R W raised shares of Vor Biopharma from a "hold" rating to a "strong-buy" rating in a research note on Wednesday, October 15th. One equities research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, three have assigned a Hold rating and two have given a Sell rating to the company's stock. Based on data from MarketBeat, the stock has an average rating of "Hold" and an average price target of $77.83.

About Vor Biopharma

Vor Biopharma, Inc, a clinical-stage company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. The company's VOR33 eHSCs lacks CD33, a protein that is expressed by AML blood cancer cells.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.